HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.

Abstract
Vascular cyclooxygenase (COX)-2-dependent prostacyclin (PGI(2)) may affect angiogenesis by preventing endothelial activation and platelet release of angiogenic factors present in platelet α-granules. Thus, a profound inhibition of COX-2-dependent PGI(2) might be associated with changes in circulating markers of angiogenesis. We aimed to address this issue by performing a clinical study with celecoxib in familial adenomatous polyposis (FAP). In nine patients with FAP and healthy controls, pair-matched for gender and age, we compared systemic biosynthesis of PGI(2), thromboxane (TX) A(2), and prostaglandin (PG) E(2), assessing their urinary enzymatic metabolites, 2,3-dinor-6-keto PGF(1α) (PGI-M), 11-dehydro-TXB(2) (TX-M), and 11-α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), respectively. The impact of celecoxib (400 mg b.i.d. for 7 days) on prostanoid biosynthesis and 14 circulating biomarkers of angiogenesis was evaluated in FAP. Intestinal tumorigenesis was associated with enhanced urinary TX-M levels, but unaffected by celecoxib, suggesting the involvement of a COX-1-dependent pathway, presumably from platelets. This was supported by the finding that in cocultures of a human colon adenocarcinoma cell line (HT-29) and platelets enhanced TXA(2) generation was almost completely inhibited by pretreatment of platelets with aspirin, a preferential inhibitor of COX-1. In FAP, celecoxib profoundly suppressed PGE(2) and PGI(2) biosynthesis that was associated with a significant increase in circulating levels of most proangiogenesis proteins but also the antiangiogenic tissue inhibitor of metalloproteinase 2. Urinary PGI-M, but not PGE-M, was negatively correlated with circulating levels of fibroblast growth factor 2 and angiogenin. In conclusion, inhibition of tumor COX-2-dependent PGE(2) by celecoxib may reduce tumor progression. However, the coincident depression of vascular PGI(2), in a context of enhanced TXA(2) biosynthesis, may modulate the attendant angiogenesis, contributing to variability in the chemopreventive efficacy of COX-2 inhibitors such as celecoxib.
AuthorsMelania Dovizio, Stefania Tacconelli, Emanuela Ricciotti, Annalisa Bruno, Thorsten Jürgen Maier, Paola Anzellotti, Luigia Di Francesco, Paola Sala, Stefano Signoroni, Lucio Bertario, Dan A Dixon, John A Lawson, Dieter Steinhilber, Garret A FitzGerald, Paola Patrignani
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 341 Issue 1 Pg. 242-50 (Apr 2012) ISSN: 1521-0103 [Electronic] United States
PMID22262921 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyclooxygenase 2 Inhibitors
  • Prostaglandins
  • Pyrazoles
  • Sulfonamides
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Thromboxane A2
  • Epoprostenol
  • Celecoxib
Topics
  • Adenomatous Polyposis Coli (blood, drug therapy)
  • Adult
  • Animals
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors (pharmacology, therapeutic use)
  • Epoprostenol (antagonists & inhibitors, biosynthesis)
  • Female
  • HT29 Cells
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Middle Aged
  • Neovascularization, Physiologic (drug effects, physiology)
  • Prostaglandins (biosynthesis, blood)
  • Pyrazoles (pharmacology, therapeutic use)
  • Sulfonamides (pharmacology, therapeutic use)
  • Thromboxane A2 (antagonists & inhibitors, biosynthesis)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: